The US FDA Accepts Levicept’s LEVI-04 IND Application for Osteoarthritis

Shots:

• The US FDA has accepted IND application for LEVI-04 for the treatment of osteoarthritis
• Levicept has completed the P-II trial of LEVI-04 in 518 patients with pain & disability due to knee OA, with ACR Convergence data showing the 1EP was met & demonstrated significant analgesia & symptom control across all doses
• Further analyses showed dose-dependent reductions in bone marrow lesion size & presence vs PBO, with lesion reduction significantly correlated with improved OA symptom scores, suggesting potential disease-modifying effects

Ref: Globenewswire | Image: Levicept  | Press Release

Related News: D3 Bio Receives the US FDA IND Clearance to Initiate P-I trial of D3S-003 & P-II Combination Study of Elisrasib (D3S-001) with D3S-002

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com